Cargando…

Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease

BACKGROUND: Metastatic uveal melanoma (UM) carries a poor prognosis; liver is the most frequent and often solitary site of recurrence. Available systemic treatments have not improved outcomes. Melphalan percutaneous hepatic perfusion (M‐PHP) allows selective intrahepatic delivery of high dose cytoto...

Descripción completa

Detalles Bibliográficos
Autores principales:	Karydis, Ioannis, Gangi, Alexandra, Wheater, Matthew J., Choi, Junsung, Wilson, Iain, Thomas, Kerry, Pearce, Neil, Takhar, Arjun, Gupta, Sanjay, Hardman, Danielle, Sileno, Sean, Stedman, Brian, Zager, Jonathan S., Ottensmeier, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033148/ https://www.ncbi.nlm.nih.gov/pubmed/29284076 http://dx.doi.org/10.1002/jso.24956

Ejemplares similares

Chemosaturation with percutaneous hepatic perfusion of melphalan for metastatic uveal melanoma
por: Modi, Sachin, et al.
Publicado: (2022)

Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma
por: Karydis, Ioannis, et al.
Publicado: (2016)

Percutaneous Hepatic Perfusion (PHP) with Melphalan in Liver-Dominant Metastatic Uveal Melanoma: The German Experience
por: Dewald, Cornelia L. A., et al.
Publicado: (2021)

Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience
por: Artzner, Christoph, et al.
Publicado: (2019)

Intra-arterial perfusion-based therapies for regionally metastatic cutaneous and uveal melanoma
por: Broman, Kristy K, et al.
Publicado: (2019)

Predictive Parameters in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan for Unresectable Liver Metastases from Uveal Melanoma: A Retrospective Pooled Analysis
por: Tong, T. M. L., et al.
Publicado: (2022)

Isolated Hepatic Perfusion With Melphalan for Patients With Isolated Uveal Melanoma Liver Metastases: A Multicenter, Randomized, Open-Label, Phase III Trial (the SCANDIUM Trial)
por: Olofsson Bagge, Roger, et al.
Publicado: (2023)

The pharmacokinetic advantages of isolated limb perfusion with melphalan for malignant melanoma.
por: Scott, R. N., et al.
Publicado: (1992)

Isolated hepatic perfusion in the pig with TNF-alpha with and without melphalan.
por: Borel Rinkes, I. H., et al.
Publicado: (1997)

Isolated Limb Perfusion with Melphalan and TNF-α in the Treatment of Extremity Sarcoma
por: Verhoef, Cornelis, et al.
Publicado: (2007)

Isolated Limb Perfusion With Melphalan Triggers Immune Activation in Melanoma Patients
por: Johansson, Junko, et al.
Publicado: (2018)

Isolated Hepatic Perfusion with 200 mg Melphalan for Advanced Noncolorectal Liver Metastases
por: van Iersel, Liselot B. J., et al.
Publicado: (2008)

The effects of perfusion conditions on melphalan distribution in the isolated perfused rat hindlimb bearing a human melanoma xenograft.
por: Wu, Z. Y., et al.
Publicado: (1997)

Multi-Modal Mass Spectrometric Imaging of Uveal Melanoma
por: Cole, Laura M., et al.
Publicado: (2021)

Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb.
por: Klaase, J. M., et al.
Publicado: (1994)

Successful use of adalimumab in immune checkpoint inhibitor-associated inflammatory arthritis
por: Oke, Anuoluwapo R, et al.
Publicado: (2018)

Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats
por: Wilt, J H W de, et al.
Publicado: (1999)

Unresectable Hepatic Metastasis of Uveal Melanoma: Hepatic Chemosaturation with High-Dose Melphalan—Long-Term Overall Survival Negatively Correlates with Tumor Burden
por: Brüning, R., et al.
Publicado: (2020)

Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion
por: de Wilt, J H W, et al.
Publicado: (2000)

TNF-alpha and melphalan-based isolated limb perfusion: no evidence supporting the early destruction of tumour vasculature
por: Podleska, L E, et al.
Publicado: (2015)

TNF-alpha and melphalan-based isolated limb perfusion: no evidence supporting the early destruction of tumour vasculature
por: Podleska, L E, et al.
Publicado: (2015)

Repeated percutaneous hepatic perfusion with melphalan can maintain long-term response in patients with liver cancers
por: Veelken, Rhea, et al.
Publicado: (2021)

Percutaneous isolated hepatic perfusion (chemosaturation) with melphalan following right hemihepatectomy in patients with cholangiocarcinoma and metastatic uveal melanoma: peri- and post-interventional adverse events and therapy response compared to a matched group without prior liver surgery
por: Dewald, C. L. A., et al.
Publicado: (2020)

Anesthesia management of patients undergoing hyperthermic isolated limb perfusion with melphalan for melanoma treatment: an analysis of 17 cases
por: Ruschulte, Heiner, et al.
Publicado: (2013)

MGMT methylation correlates with melphalan pelvic perfusion survival in stage III melanoma patients: a pilot study
por: Guadagni, Stefano, et al.
Publicado: (2017)

ASO Author Reflections: Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Hepatic Metastases from Ocular Melanoma
por: Meijer, T. Susanna, et al.
Publicado: (2020)

Prospective evaluation of percutaneous hepatic perfusion with melphalan as a treatment for unresectable liver metastases from colorectal cancer
por: Meijer, T. Susanna, et al.
Publicado: (2022)

Percutaneous hepatic melphalan perfusion: Single center experience of procedural characteristics, hemodynamic response, complications, and postoperative recovery
por: Struck, Manuel Florian, et al.
Publicado: (2021)

Decreased melphalan accumulation in a human breast cancer cell line selected for resistance to melphalan.
por: Moscow, J. A., et al.
Publicado: (1993)

Meta-Analysis of Isolated Hepatic Perfusion and Percutaneous Hepatic Perfusion as a Treatment for Uveal Melanoma Liver Metastases
por: Bethlehem, Martijn S., et al.
Publicado: (2021)

Over 12 Years Single Institutional Experience Performing Percutaneous Hepatic Perfusion for Unresectable Liver Metastases
por: Carr, Michael J., et al.
Publicado: (2020)

Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
por: Lee, Se Ryeon, et al.
Publicado: (2019)

Increasing the effective concentration of melphalan in experimental rat liver tumours: comparison of isolated liver perfusion and hepatic artery infusion.
por: Marinelli, A., et al.
Publicado: (1991)

Liver and tumour tissue concentrations of TNF-alpha in cancer patients treated with TNF-alpha and melphalan by isolated liver perfusion.
por: Kuppen, P. J., et al.
Publicado: (1997)

Isolated limb perfusion with melphalan activates interferon-stimulated genes to induce tumor regression in patients with melanoma in-transit metastasis
por: Johansson, Junko, et al.
Publicado: (2019)

Factors influencing the chemosensitization of melphalan by misonidazole.
por: Randhawa, V. S., et al.
Publicado: (1985)

Evaluation of immune infiltration in the colonic mucosa of patients with ipilimumab-related colitis
por: Arriola, Edurne, et al.
Publicado: (2016)

Gastrointestinal Bleeding Secondary to High-Dose Melphalan Pretreatment in Patients with Multiple Myeloma Was Associated with the Mode of Melphalan Administration
por: Ge, Qunfang, et al.
Publicado: (2022)

Evaluation of Delcath Systems’ Generation 2 (GEN 2) Melphalan Hemofiltration System in a Porcine Model of Percutaneous Hepatic Perfusion
por: Moeslein, Fred M., et al.
Publicado: (2014)

Surgical versus percutaneous isolated pelvic perfusion (IPP) for advanced melanoma: comparison in terms of melphalan pharmacokinetic pelvic bio-availability
por: Guadagni, Stefano, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_bi2hc73058mq2qe7qeu518irer